ORMPORAMED PHARMACEUTICALS INC.vs its industry peers
A metric-by-metric comparison of ORAMED PHARMACEUTICALS INC. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORMP본 종목 | $168M#7 | 1.0x#2 | 0.8x#5 | 84.2x#6 | — | 573.1%#1 | -754.4%#5 | 0.0%#2 | -4.4%#1 | — | 70.5%#2 | — |
| INO | $181M#1 | — | 41.4x#14 | 2769.2x#7 | -70.0%#6 | 20.6%#6 | -132871.3%#7 | -1944.6%#15 | -243.9%#4 | — | — | — |
| UPB | $176M#2 | — | 0.6x#3 | 61.6x#4 | 20.4%#2 | -128.4%#12 | -5618.8%#6 | -52.9%#8 | — | — | — | — |
| ALXO | $176M#3 | — | 1.3x#6 | — | — | 24.6%#5 | — | -74.7%#10 | -84.4%#3 | — | — | — |
| CNTN | $170M#4 | — | 0.4x#1 | — | — | -194.5%#13 | — | -7.9%#5 | — | — | — | — |
| SION | $169M#5 | — | 0.6x#2 | — | — | -22.0%#11 | — | -28.3%#6 | — | — | — | — |
| ANTX | $168M#6 | — | 2.2x#8 | — | — | 31.5%#3 | — | -46.3%#7 | — | — | 269.0%#1 | — |
| CURX | $168M#8 | — | 35.1x#13 | — | — | -1068.8%#14 | — | -88.2%#12 | — | — | -61.2%#4 | — |
| PEPG | $162M#9 | — | 1.4x#7 | — | — | 0.4%#7 | — | -75.0%#11 | — | — | -49.9%#3 | — |
| MBRX | $158M#10 | 0.6x#1 | 13.6x#11 | — | — | 28.8%#4 | — | 289.6%#1 | — | — | — | — |
| MGNX | $156M#11 | — | 3.6x#9 | 1.0x#1 | -0.3%#4 | -11.4%#9 | -48.7%#1 | -0.2%#4 | — | — | — | — |
| CUE | $154M#12 | — | 66.7x#15 | 5.6x#2 | 195.7%#1 | 34.6%#2 | -96.7%#2 | -1151.6%#14 | — | — | — | — |
| KRSA | $147M#13 | — | 28.9x#12 | 70.9x#5 | 3.7%#3 | -15.4%#10 | -239.8%#3 | -69.4%#9 | -69.1%#2 | — | — | — |
| RNA | $145M#14 | — | 0.7x#4 | — | — | — | — | 0.0%#3 | — | — | -87.9%#5 | — |
| PYXS | $142M#15 | — | 12.4x#10 | 10.3x#3 | -14.2%#5 | -3.0%#8 | -609.2%#4 | -696.0%#13 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice